Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis-Reference-Cited by-同舟云学术

Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis

Published:2012-01-27 Issue:6 Volume:68 Page:969-977
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Björkman Sven,Åhlén Victor

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-012-1211-z.pdf

Reference38 articles.

1. Escobar MA (2003) Treatment on demand—in vivo dose finding studies. Haemophilia 9:360–367

2. World Federation of Hemophilia (2008) Protocols for the treatment of hemophilia and von Willebrand disease, 3rd edn. Treatment of Hemophilia monograph no 14. Available at: http://www.wfh.org/2/docs/Publications Accessed 16 June 2010.

3. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H (1992) Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Int Med 232:25–32

4. Björkman S (2003) Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 9[Suppl 1]:101–110

5. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S (2011) Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 17:2–10

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How much prophylaxis is enough in haemophilia?;Haemophilia;2024-03-24

2. Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B;Research and Practice in Thrombosis and Haemostasis;2024-03

3. A new population pharmacokinetic model for recombinant factor IX‐Fc fusion concentrate including young children with haemophilia B;British Journal of Clinical Pharmacology;2023-09-12

4. Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study);TH Open;2022-01

5. How do we optimally utilize factor concentrates in persons with hemophilia?;Hematology;2021-12-10